Global Navigation
Pfizer/ Medivation AD drug fails trial
Pfizer and Medivation's Alzheimer's Disease (AD) treatment, Dimebon (latrepirdin), has failed to meet its co-primary or secondary efficacy endpoints in a phase III trial.
The phase III, multi-national, double-blind, placebo-controlled ,CONNECTION trial, involved 598 patients with mild-to-moderate AD.
Dr David Hung, president and CEO of Medivation, said: "The results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer's community."
He went on to say that Medivation would be working with Pfizer to analyse the data from the trial.
Dr Briggs W Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer said: "We recognise the significant medical need, and we are committed to advancing treatment options for Alzheimer's disease."
Both the CONNECTION study and a separate phase III study found Dimebon to be well tolerated when dosed alone or in combination with other approved AD therapies.
Dimebon is being studied in four other ongoing randomised, double-blind, placebo-controlled phase III studies, which currently are enrolling.
Medivation and Pfizer have a global collaboration to develop and commercialise Dimebon for the treatment of Alzheimer's disease and Huntington's disease. Under the terms of the agreement, the companies work together on the Dimebon development programme.
Published: 04/03/2010
Content Area: Pharmaceutical industry articlesArticle type: Healthcare news
